Journal of Cardiac Failure
Volume 13, Issue 6 , Pages 422-430 , August 2007

High Prevalence of Renal Dysfunction and Its Impact on Outcome in 118,465 Patients Hospitalized With Acute Decompensated Heart Failure: A Report From the ADHERE Database

  • J. Thomas Heywood, MD, FACC

      Affiliations

    • From the Scripps Clinic, La Jolla, California
    • Corresponding Author InformationReprint requests: J. Thomas Heywood, MD, Director Heart Failure Program, Scripps Clinic, 10666 N. Torrey Pines Road, SW 206, La Jolla, CA 92037.
    • ,
  • Gregg C. Fonarow, MD, FACC

      Affiliations

    • University of California Los Angeles, Los Angeles, California
    • ,
  • Maria Rosa Costanzo, MD, FACC

      Affiliations

    • Midwest Heart Specialists, Naperville, Illinois
    • ,
  • Vandana S. Mathur, MD

      Affiliations

    • MathurConsulting, Woodside, California
    • ,
  • John R. Wigneswaran, MD

      Affiliations

    • Scios Inc., Fremont, California
    • ,
  • Janet Wynne, MS

      Affiliations

    • Scios Inc., Fremont, California
    • ,
  • for the ADHERE Scientific Advisory Committee and Investigators

Received 11 January 2007 ,Revised 14 March 2007 ,Accepted 23 March 2007.

References 

  1. DeFrances CJ, Hall MJ. 2002 National Hospital Discharge Survey. Adv Data. 2004;1–29
  2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation. 2005;112:1825–1852
  3. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med. 2000;160:685–693
  4. Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384–416
  5. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115–1140
  6. Kittleson M, Hurwitz S, Shah MR, Nohria A, Lewis E, Givertz M, et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol. 2003;41:2029–2035
  7. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001;104:1985–1991
  8. Hillege HL, Girbes ARJ, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–210
  9. Fonarow GC, Adams KF, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572–580
  10. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  11. Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design and preliminary observations from the Acute Decompensated Heart Failure National Registry (ADHERE®). Am Heart J. 2005;149:209–216
  12. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the ADHERE registry. J Am Coll Cardiol. 2005;46:57–64
  13. Fonarow GC, Yancy CW, Heywood JT. Adherence to Heart Failure Quality-of-Care Indicators in US Hospitals: analysis of the ADHERE Registry. Arch Intern Med. 2005;165:1469–1477
  14. Redfield MM. Heart failure—an epidemic of uncertain proportions. N Engl J Med. 2002;347:1442–1444
  15. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12
  16. United States Renal Data System . USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005;
  17. Cooper WA, O'Brien SM, Thourani VH, Guyton RA, Bridges CR, Szczech LA, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation. 2006;113:1063–1070
  18. Palmer BF. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises. Nephrol Dial Transplant. 2003;18:1973–1975
  19. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491
  20. Mentzer RM, Mehmet C, Sladen RN, Graeve AH, Hebeler RF, Luber JM, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: The NAPA trial. J Am Coll Cardiol. 2007;49:716–726
  21. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675
  22. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–781
  23. Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Grady D, Shlipak MG. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol. 2004;44:1593–1600
  24. Williams SC, Koss RG, Morton DJ, Loeb JM. Performance of top-ranked heart care hospitals on evidence-based process measures. Circulation. 2006;114:558–564
  25. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J. 2006;27:1216–1222
  26. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61–67
  27. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–1353
  28. Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, et al. Correlates and impact on outcomes of worsening renal function in patients 65 years of age with heart failure. Am J Cardiol. 2000;85:1110–1113
  29. Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?. J Card Fail. 2003;9:13–25
  30. Aronson D, Mittleman MA, Burger AJ. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med. 2004;116:466–473
  31. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581–2587
  32. Heywood JT, Elatre W, Pai RG, Fabbri S, Huiskes B. Simple clinical criteria to determine the prognosis of heart failure. J Cardiovasc Pharmacol Ther. 2005;10:173–180
  33. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987–1996
  34. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–678

 The ADHERE database and this study were sponsored by Scios Inc., Fremont, California.Conflicts of Interest Disclosure: J. Thomas Heywood, MD, has a consultant/or advisory board relationship with GlaxoSmithKline, Medtronic, Inc., and Scios Inc. He is on the speaker's bureaus for and has received honoraria from GlaxoSmithKline, Guidant Corporation, Medtronic, Inc., Pfizer Inc., and Scios Inc. He has received research grant support from GlaxoSmithKline; Medtronic, Inc.; Sanofi-Aventis; Scios Inc.; and St. Jude Medical.Gregg C. Fonarow, MD, has a consultant/or advisory board relationship with Scios Inc.'s Steering Committee for the ADHERE Core, EM, and Longitudinal Registries. He is on the speaker's bureau for and has received honoraria from Scios Inc. He has received research grant support from Scios Inc.'s ADHERE Registries and CHF Solutions, Inc.'s UNLOAD Trial.Maria Rosa Costanzo, MD, has a consultant/or advisory board relationship with CHF Solutions, Inc. and Scios Inc. She has received honoraria from CHF Solutions, Inc. and Medtronic, Inc.Vandana S. Mathur, MD, has a consultant/or advisory board relationship with Acologix, Inc.; Corgentech Inc.; FlowMedica, Inc.; Ingenix; Ortho Biotech; RenaMed Biologics; Scios Inc.; Synecor, LLC; and XenoPort, Inc. She is on the speaker's bureau for Scios Inc. She has received honoraria from GE Healthcare and Scios Inc.John R. Wigneswaran, MD, is a former employee of Scios Inc. Before his employment with Scios Inc., he was on the speaker's bureau for Scios Inc. and received honoraria from Scios Inc. He is aware that at the time of his employment at Scios Inc., Scios Inc. funded this article. He owns stock in Johnson & Johnson.Janet Wynne, MS, is an employee of Scios Inc. She owns stock in Johnson & Johnson. She is aware that Scios, Inc. is the sponsor of the ADHERE database.

PII: S1071-9164(07)00103-0

doi: 10.1016/j.cardfail.2007.03.011

Journal of Cardiac Failure
Volume 13, Issue 6 , Pages 422-430 , August 2007

Article Tools

* Image Usage & Resolution